AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04549623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpO2 and respiratory motion monitoring
Description: Finger SpO2 and ECG-based respiratory motion monitoring are used during operation.
Study NCT00868751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: Initial therapy: Tocilizumab dosed by body weight (8mg/kg based on body weight ≥ 30kg) given by intravenous infusion every two weeks for 12 weeks.~Extension of therapy: Continuation of treatment with tocilizumab at 8mg/kg by body weight given by intravenous infusion every 2 weeks based upon achievement of Primary Objective by week 12, OR continuation of treatment with escalation of tocilizumab dose to 12mg/kg by body weight, given by intravenous infusion every two weeks, for failure to achieve ACR JIA30 at 12 weeks or ACR JIA50 response at any time after week 16.
Study NCT03510078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin for glycemic control according to the allocation
Study NCT02770768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flibanserin
Description: Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
Study NCT02770768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
Study NCT00825981 — intervention group
Intervention type: OTHER
Intervention: screening coagulation abnormalities
Description: if specific coagulation abnormalities are observed which increase patient's risk of bleeding, appropriate treatment will start
Study NCT01158014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fibrin Glue, Quixil
Description: quixil 0.1 ml
Study NCT01158014 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: vicryl 10/0
Study NCT00564395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Detemir mixed with RAI injection
Description: Insulin Detemir mixed with RAI injection is given twice daily as subcutaneous injection
Study NCT00564395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Detemir and RAI injection
Description: Insulin detemir and RAI are given as separate injections, twice daily as subcutaneous injection
Study NCT03474146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ocimum sanctum
Description: Ocimum sanctum (known as Tulsi, Holy basil) is natural herb which is known for its broad spectrum medicinal properties. Ocimum sanctum is one of the best examples of Ayurveda's holistic lifestyle approach to health. It is also been well practiced in traditional medicine in India and south Asian region. Literature showed that Ocimum sanctum extract have significant anti-gingivitis and anti-inflammatory effect as mouthrinse.
Study NCT03474146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: Chlorhexidine Gluconate (C34H54Cl2N10O14) is a bisbiguanide formulation with cationic properties. Chlorhexidine over a period of over 40 years has been thoroughly investigated and successfully used as plaque control agent in dental practice. A literature review, highlighting chlorhexidine as not only a plaque control agent but also as an effective antimicrobial agent and its wider application in variety of oral disorders in various formulations.
Study NCT03474146 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Propylene Glycol
Description: Propylene glycol or 1,2-dihydroxypropane or 1,2-propanediol, is a clear, colourless, viscous, practically odourless liquid with a density of 1.038 g/cm³ at 20 °C and a molecular weight of 76.095. It is miscible with water, acetone and chloroform. It is miscible in water. Propylene glycol is commonly used as an excipient in a variety of drugs and it is also authorised in food products and cosmetics.
Study NCT02509975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostate artery embolization.
Description: Embolization of the prostatic vasculature with OCL 503 using a microcatheter.
Study NCT00856843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI800
Description: Solution for oral administration prior to colonoscopy
Study NCT00856843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol 3350 based bowel preparation
Description: Solution for oral administration prior to colonoscopy
Study NCT04365049 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy
Description: Radiotherapy started after two cycles of chemotherapy. External beam radiation therapy was performed using an intensity modulated radiation therapy technique. The gross target volume included the gross primary tumor and positive regional lymph nodes as defined by the multiphasic imaging. A total radiation dose greater than 50 Gy without damaging organ function was the essential requirement.
Study NCT04365049 — intervention group
Intervention type: DRUG
Intervention: Nab-paclitaxel
Description: Eight 21-day cycles of nab-paclitaxel 125 mg/m² by intravenous infusion for approximately 30-45 mins on days 1 and 8.
Study NCT04365049 — intervention group
Intervention type: DRUG
Intervention: Gemcitabine
Description: Eight 21-day cycles of gemcitabine 1000mg/m² intravenous infusion for approximately 30 mins on days 1 and 8.
Study NCT04365049 — intervention group
Intervention type: DRUG
Intervention: Camrelizumab
Description: Anti-PD-1 antibody (camrelizumab, Hengrui Medicine Co., Ltd) 200 mg was administered intravenously for 30 mins every three weeks. During the chemotherapy-treated period, camrelizumab was administered on day 1 of each 21-day cycle before the infusion of chemotherapy.
Study NCT03529344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blue whiting protein hydrolysate
Description: Dietary Supplement: Blue whiting protein hydrolysate 6g protein per day for 6wk
Study NCT03529344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Control
Description: Control group will receive non-caloric juice without protein supplementation
Study NCT01781052 — intervention group
Intervention type: DRUG
Intervention: Ventavis (Iloprost, BAYQ6256)
Description: Initial dose: 2.5 µg per inhalation session; 6-9 inhalations/day. Dose can be increased to up to 5.0 µg per inhalation session.
Study NCT03129113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: 1:1:1:1 randomisation to one of four arms for 48 weeks
Study NCT03129113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1:1:1:1 randomisation to one of four arms for 48 weeks
Study NCT02636439 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary, aerobic and resistance training
Description: hypocaloric diet individual exercise prescription for aerobic training individual exercise prescription for resistance training.
Study NCT02636439 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary, and aerobic exercise
Description: hypocaloric diet individual prescription for aerobic training.
Study NCT02507024 — intervention group
Intervention type: OTHER
Intervention: Online questionnaire
Study NCT04879836 — intervention group
Intervention type: DEVICE
Intervention: Teething Gel
Description: Dosage: application of an even coat of 1mm thickness Frequency: 5 times/day (after main meals and before sleeping) Duration: 4 weeks
Study NCT04879836 — intervention group
Intervention type: DEVICE
Intervention: Teething Ring
Description: The teething ring was filled with a coolant Usage: 5/10 min per time Frequency: 5 times/day Duration: 4 weeks
Study NCT04505618 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Swept-Source (SS) OCT Angiography
Description: Non-invasive, minimal risk, ocular imaging study
Study NCT03360110 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stenfilcon A lens (control)
Description: Daily disposable contact lens
Study NCT00947141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganciclovir (start when CMV PCR >200copies / ml x2)
Description: Group A: Start ganciclovir when CMV PCR >200copies / ml x 2) . Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased > 3,000. If treated (and monitored) treat until \<200 copies on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B
Study NCT00947141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitor (Treatment starts when CMV PCR >3,000 copies / ml)
Description: Group A: CMV viral load between 200-3,000 copies/ml (on 2 occasions). Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased > 3,000. If treated (and monitored) treat until \<200 copies on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B
Study NCT00947141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stop treatment when 2 levels CMV PCR <3,000 copies / ml
Description: Group B: Viral load > 3,000 copies/ml. Participants are randomised to treat until \< 3,000 copies/ml on 2 occasions or treat until \<200 copies/ml on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B
Study NCT00947141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitor (Treatment stops CMV PCR <200 copies / ml x2)
Description: Group B: Viral load > 3,000 copies/ml. Participants are randomised to treat until \< 3,000 copies/ml on 2 occasions or treat until \<200 copies/ml on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B
Study NCT02725528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: collagenase injection
Description: injection
Study NCT02725528 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: limited palmar fasciectomy
Description: surgery
Study NCT03866447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D analog
Description: Patients will be clinically and photographically evaluated at baseline and at each follow up visit every month for 3 months. Any local or systemic clinical side effects of the medications will be noted during each follow up visit.
Study NCT03866447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene
Description: Patients will be clinically and photographically evaluated at baseline and at each follow up visit every
Study NCT00444262 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hemodynamic optimisation guided using esophageal Doppler
Description: hemodynamic optimisation guided using esophageal Doppler
Study NCT00444262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VOLUVEN and others solute
Description: VOLUVEN and others solute
Study NCT01582373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral couple therapy
Description: The treatment package will include the following: information about the nature of CBCT; education about PVD and how it impacts on sexuality; education concerning a multifactorial view of pain; relaxation techniques; vaginal dilatation exercises; cognitive restructuring exercises (replacing distorted or irrational beliefs about pain and sexuality by more realistic ones); distraction techniques focusing on sexual imagery; expansion of the sexual repertoire; and exercises to improve pain and sexuality-relevant couple interactions (e.g., communication skills training, modification of maladaptive partner responses to pain, emotional disclosure and validation exercises).
Study NCT04207645 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Modified RIPASA score
Description: Clinical Prediction Rules consist of clinical and laboratory parameters to aid diagnosis of acute appendicitis
Study NCT02594410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stent
Description: patients receiving renal artery stenting for renal artery atherosclerosis
Study NCT02594410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirine
Description: 100mg Qd
Study NCT02594410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 75mg Qd
Study NCT02594410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine
Description: 10-20mg Qd
Study NCT01748045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide
Study NCT01748045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator - nitrogen gas
Study NCT00932295 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OB
Description: 10 puffs from the participants own brand brand of cigarette (lit; 30 second inter puff interval)
Study NCT00932295 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham smoking
Description: 10 puffs from the participants own brand brand of cigarette (NOT lit; 30 second inter puff interval)
Study NCT00932295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CROWN SEVEN
Description: 10 puffs from a so-called electronic cigarette named CROWN SEVEN (16 mg cartridge; 30 second inter puff interval)
Study NCT00932295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NJOY
Description: 10 puffs from a so-called electronic cigarette named NJOY(16 mg cartridge; 30 second inter puff interval)
Study NCT02925845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrostimulation
Description: The device CompexTheta 400i provided with various developmental programs rehabilitation exercise with different phases, types and current is used. an adaptive program (heating, toning, muscular atrophy, strength-endurance) will be established for each patient during the study period. It shall apply at the level of the muscle bellies of the flexor and extensor muscles of the forearm dela upper extremity AV created. Electrodes are positioned at the anatomical reference positions. The intensity of the current will increase until a tolerable muscle contraction and painless by the patient.
Study NCT00778921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Description: Amlodipine 10 mg
Study NCT00778921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 150
Description: Aliskiren/Amlodipine 150/10 mg
Study NCT00778921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 300
Description: Aliskiren/Amlodipine 300/10 mg
Study NCT01686490 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Video/workbook for patients about to receive an AICD
Description: will view the 3 completed sections of the video/workbook
Study NCT01686490 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LiveSkills Video/Workbook for patients about to receive an AICD
Description: This exploratory intervention first met in a focus group with healthcare professionals and another focus group with patients who already had received an automatic implantable cardiac defibrillator to learn more about what video and accompanying workbook material it would be helpful for patients to receive pre-inplantation. Another focus group was held with post-implantation patients asking them what additional knowledge would have been helpful. Three sections of the video with accompanying workbook were then produced and given to pre-inplantation patients. A focus group was then held with these patients after their procedure to ask them what had and had not proved helpful.
Study NCT02132117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline HCL Cream 1.0%
Description: Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 29 days.
Study NCT04505618 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Spectral-Domain (SD) OCT Angiography
Description: Non-invasive, minimal risk, ocular imaging study
Study NCT02132117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle to Oxymetazoline HCL Cream
Description: Vehicle to Oxymetazoline HCL Cream (AGN-199201) applied to the face once daily for 29 days.
Study NCT05907642 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Prune (dried plum)
Description: Subjects who are assigned to the treatment group consume a total of 100 g of prune per day for 18 days and the subjects who are assigned to the control group are allowed to have a normal meal without prune for 18 days.
Study NCT05907642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prune (dried plum)
Description: Subjects who are assigned to the treatment group consume a total of 100 g of prune per day for 18 days and the subjects who are assigned to the control group are allowed to have a normal meal without prune for 18 days.
Study NCT03553290 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A.R.C. FOX Laser-FOX Q-810nm
Description: 805-810 nm dichotomous laser, 12 Watt within the power of sensitive parts of the affected teeth
Study NCT03553290 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Mechanical debridement alone
Study NCT04627415 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Engagement with ADHD Pre-Kindergarteners
Description: Optimism Training includes the following strategies: 1) Identifying situations and associations 2) Determining consequences of beliefs 3) Use distractions to interrupt negative thinking 4) dispute current thinking 5) substitute positive, productive thoughts 6) practice skills to recognize/modify self-talk 7) Maintain positive changes in self-talk
Study NCT04627415 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Promoting Engagement with ADHD Pre-Kindergarteners
Description: Optimism Training includes the following strategies: 1) Identifying situations and associations 2) Determining consequences of beliefs 3) Use distractions to interrupt negative thinking 4) dispute current thinking 5) substitute positive, productive thoughts 6) practice skills to recognize/modify self-talk 7) Maintain positive changes in self-talk
Study NCT04246853 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) of the resting state motor network
Description: Transcranial direct current stimulation (tDCS) delivers a low intensity current of up to 4 mA per session through small and circular shaped electrodes applied over the scalp. This induces a weak but focal electrical field that may modify the excitability of the underlying cortical target in a polarity and activity dependent fashion.
Study NCT04246853 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) of the resting state motor network
Description: Transcranial direct current stimulation (tDCS) delivers a low intensity current of up to 4 mA per session through small and circular shaped electrodes applied over the scalp. This induces a weak but focal electrical field that may modify the excitability of the underlying cortical target in a polarity and activity dependent fashion.
Study NCT02621554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: resveratrol supplementation
Description: 6 months of resveratrol supplementation
Study NCT02621554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 months of placebo intake
Study NCT01949883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-0610
Study NCT02760485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itacitinib
Description: Phase 1 will evaluate itacitinib at the protocol-specified starting dose, with a possible increase or decrease depending on tolerability. Phase 2 will evaluate the recommended dose determined in Phase 1.
Study NCT02760485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Study NCT03108638 — intervention group
Intervention type: BEHAVIORAL
Intervention: R3 Supervisor Implementation Strategy
Description: Supervisors will be trained to provide supervision to their caseworkers using R3 principles and strategies. Monthly monitoring and remote coaching will be provided.
Study NCT01427738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentian Violet
Description: Participants were administered topical Gentian violet solution, orally, twice daily for 14 days.
Study NCT01427738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nystatin oral suspension
Description: Participants were administered Nystatin oral suspension 4 times a day for 14 days.
Study NCT05127018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injection of Botulinum type A
Description: The participates were allocated to two different application methods: Simplified Method for the first injection and Individualized Method 8 months later. All the patients underwent twice injection with each methods with no change of the BTX-A(Botox, Allergan, Irvine, CA) and other injection details: Lyophilized 100 U of Botox was reconstituted in 2.5 mL of 0.9% sodium chloride solution. The injections were made with a 27-gauge insulin syringe. The treatment was an outpatient procedure and all injections were performed by one of the authors (X.G.). No anesthesia was given during the procedure.